e-therapeutics presents new data supporting ETX‑312 as a differentiated, disease-modifying near-clinic GalOmic Treatment for MASH
London, UK, 07 May 2025 – e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced it will present new preclinical results on its GalOmic small‑interfering RNA (siRNA) candidate ETX‑312 for the treatment of metabolic dysfunction‑associated steatohepatitis (MASH) at the European Association for the Study of the Liver (EASL) Congress, 7th-10th May 2025.
In the leading Gubra‑Amylin NASH diet‑induced obese (GAN‑DIO) mouse model, ETX‑312 demonstrated:
- Significant improvements in NAFLD Activity Score (NAS) when administered as monotherapy or in combination with a GLP‑1/GIP receptor agonist or an FGF‑21 analogue. All mice receiving combination therapy achieved ≥ 2‑point reductions in NAS, with improvements of up to 5 points observed.
- Slowed fibrosis progression comparable to that achieved with GLP‑1/GIP receptor agonist or FGF‑21 analogue controls, supported by statistically significant reductions in hepatic collagen staining and in circulating biomarkers TIMP‑1 and PIIINP.
“These data add to a growing body of evidence supporting ETX-312 as a differentiated, disease-modifying therapy for MASH,” said Alan Whitmore, Chief Scientific Officer, “We are excited to progress the programme towards the clinic.”
ETX‑312 is currently in IND‑enabling studies, and the Company remains on track to submit a regulatory submission by the end of 2025.
Presentation Details
Title: ETX-312, a GalOmic siRNA for the treatment of MASH, effectively improves the MASH phenotype of GAN DIO-MASH mice alone or in combination with emerging therapies
Poster Number: FRI-337
Date: 9th May 2025
About ETX-312
ETX‑312 is a GalOmic GalNAc-conjugated small-interfering RNA (GalNAc-siRNA) therapeutic candidate in development to be a safe and effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) with potential for a quarterly subcutaneous dosing regimen. In preclinical studies using the Gubra-Amylin NASH diet-induced obese (GAN‑DIO) mouse model, administration of ETX-312 led to reductions in NAFLD Activity Score (NAS), decreased hepatic inflammation, and slowed fibrosis progression, both as a monotherapy and in combination with emerging therapies. ETX-312 is currently progressing through IND-enabling studies, with a regulatory submission planned by the end of 2025.